Daily FNArena News - Small Caps

UXC has signalled an improvement in the second half and brokers believe conservative forecasts belie the IT service provider’s potential.

Tox Free Solutions has disappointed brokers, providing weak FY14 guidance in the face of a subdued industrial outlook and delays to contract settlments.

Reckon will buy back the stake held by Intuit, severing ties with the direct competitor.

Brokers believe automotive parts distributor Burson is well placed to capitalise on opportunities.

Bell Potter initiates coverage on Mayne Pharma and takes a contrary stance to other brokers.

PS&C had to make its first downgrade to guidance since listing on ASX amidst generalised weakness in the IT sector.

CLSA learns Cover-More is protected against some of the pitfalls for travel insurers, changing tack on the stock. Bell Potter also initiates coverage with a Buy rating.

Baillieu Holst takes a look at the significant upside for Cellmid’s cancer targeting technology.

Virtus Health has made its first acquisition since listing, a 70% stake in an Irish IVF clinic.

Stem cell developer Cynata Technologies has found a fan in Baillieu Holst because of the potential to revolutionise regenerative medicine.